BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24116146)

  • 1. Meta-analysis identifies NF-κB as a therapeutic target in renal cancer.
    Peri S; Devarajan K; Yang DH; Knudson AG; Balachandran S
    PLoS One; 2013; 8(10):e76746. PubMed ID: 24116146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK/NF-κB/IκBα pathway.
    Ch'ng WC; Abd-Aziz N; Ong MH; Stanbridge EJ; Shafee N
    Cell Oncol (Dordr); 2015 Aug; 38(4):279-88. PubMed ID: 25930675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High VHL Expression Reverses Warburg Phenotype and Enhances Immunogenicity in Kidney Tumor Cells.
    Zhu S; Ding W; Chen Y; Wang W; Xu R; Liu C; Liu X; Deng H
    Genomics Proteomics Bioinformatics; 2022 Aug; 20(4):657-669. PubMed ID: 33647481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas.
    Pantuck AJ; An J; Liu H; Rettig MB
    Cancer Res; 2010 Jan; 70(2):752-61. PubMed ID: 20068166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus.
    Roos FC; Roberts AM; Hwang II; Moriyama EH; Evans AJ; Sybingco S; Watson IR; Carneiro LA; Gedye C; Girardin SE; Ailles LE; Jewett MA; Milosevic M; Wilson BC; Bell JC; Der SD; Ohh M
    EMBO Mol Med; 2010 Jul; 2(7):275-88. PubMed ID: 20623734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
    Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
    J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
    Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
    Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VHL promotes immune response against renal cell carcinoma via NF-κB-dependent regulation of VCAM-1.
    Labrousse-Arias D; Martínez-Alonso E; Corral-Escariz M; Bienes-Martínez R; Berridy J; Serrano-Oviedo L; Conde E; García-Bermejo ML; Giménez-Bachs JM; Salinas-Sánchez AS; Sánchez-Prieto R; Yao M; Lasa M; Calzada MJ
    J Cell Biol; 2017 Mar; 216(3):835-847. PubMed ID: 28235946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
    Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
    Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
    Hong B; Cai L; Wang J; Liu S; Zhou J; Ma K; Zhang J; Zhou B; Peng X; Zhang N; Gong K
    Clin Genitourin Cancer; 2019 Apr; 17(2):97-104.e1. PubMed ID: 30522901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging role of nuclear factor kappa B in renal cell carcinoma.
    Morais C; Gobe G; Johnson DW; Healy H
    Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
    Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
    BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization.
    Nowicka AM; Häuselmann I; Borsig L; Bolduan S; Schindler M; Schraml P; Heikenwalder M; Moch H
    Oncogene; 2016 Jun; 35(24):3125-38. PubMed ID: 26500060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
    Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
    Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation of clear cell and non-clear cell renal cell carcinomas by all-relevant radiomics features from multiphase CT: a VHL mutation perspective.
    Li ZC; Zhai G; Zhang J; Wang Z; Liu G; Wu GY; Liang D; Zheng H
    Eur Radiol; 2019 Aug; 29(8):3996-4007. PubMed ID: 30523454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.
    Zhang J; Wu T; Simon J; Takada M; Saito R; Fan C; Liu XD; Jonasch E; Xie L; Chen X; Yao X; Teh BT; Tan P; Zheng X; Li M; Lawrence C; Fan J; Geng J; Liu X; Hu L; Wang J; Liao C; Hong K; Zurlo G; Parker JS; Auman JT; Perou CM; Rathmell WK; Kim WY; Kirschner MW; Kaelin WG; Baldwin AS; Zhang Q
    Science; 2018 Jul; 361(6399):290-295. PubMed ID: 30026228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis.
    Dong B; Gao Y; Kang X; Gao H; Zhang J; Guo H; You MJ; Xue W; Cheng J; Huang Y
    Oncotarget; 2016 Dec; 7(49):80435-80449. PubMed ID: 27741516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
    Brugarolas J
    Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of β2-Adrenergic Receptor Reduces Inflammation and Oxidative Stress in Clear Cell Renal Cell Carcinoma.
    Albiñana V; Recio-Poveda L; González-Peramato P; Martinez-Piñeiro L; Botella LM; Cuesta AM
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.